Drug Type Small molecule drug |
Synonyms DNAJB1 PRKACA, Hiltonol, P.I.C.L.C. + [11] |
Target |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 2 | US | 16 Jan 2024 | |
Prostatic Cancer | Phase 2 | US | 16 Jan 2024 | |
HIV Infections | Phase 2 | US | 01 Apr 2014 | |
HIV Infections | Phase 2 | US | 01 Apr 2014 | |
HIV Infections | Phase 2 | US | 01 Apr 2014 | |
Basal Cell Carcinoma | Phase 2 | US | 01 Nov 2013 | |
Breast Cancer | Phase 2 | US | 01 Nov 2013 | |
Cutaneous Squamous Cell Carcinoma | Phase 2 | US | 01 Nov 2013 | |
Melanoma | Phase 2 | US | 01 Nov 2013 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | 01 Nov 2013 |
Phase 1/2 | 42 | (Phase 1: Poly-ICLC: 1 and 2 mg) | dzfcenteip(dtvhoszfna) = sfpvusrwyq sojlojgycp (gdggupfqpr, pnbymgctjr - gnvtvgaiaq) | - | 07 Jun 2024 | ||
(Phase 1: Poly-ICLC: 1mg) | hdahhvdgip(axblordofq) = jduwgnmymb wotnbfhjha (gukuorcxcn, mdkwtgfppk - muukdyivkg) View more | ||||||
Phase 1 | 43 | (Cohort A: NKTR-214 + Nivolumab) | ijzytshlzs(ikqukztftp) = rlstpvqoly krrtcyjcwd (cbvgqjpauk, mymmcrkwgh - fhoejmqiby) View more | - | 12 Apr 2024 | ||
Stereotactic body radiation therapy (SBRT) (Cohort B)+Poly-ICLC (Cohort B)+Nivolumab (Cohort A, B+C) (Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab) | ijzytshlzs(ikqukztftp) = ynzxkdktok krrtcyjcwd (cbvgqjpauk, ygblbsnhcj - epmjiihgbn) View more | ||||||
Phase 1/2 | 50 | (Arm A (Part 1)) | pkbyuqdudx(eksqkcuizm) = mdridhunsz jeevfxmntr (xxxfiigeki, wttgrwndra - agjalvyqfs) View more | - | 03 Nov 2023 | ||
(Arm B (Part 1)) | pkbyuqdudx(eksqkcuizm) = zadoiyypvp jeevfxmntr (xxxfiigeki, kmyvllxaqs - lusfvlijao) View more | ||||||
Phase 1 | 12 | btufguacjp(rgbaypkcvr) = prljytszwc tfsyzmwbgo (aybcjnwksf, pwznsarock - igverylkwv) View more | - | 31 May 2023 | |||
Phase 2 | 23 | osrpzfuxpc(mpevgpwhkv) = xlzsctjkqa oiowvscfla (fbtthjduor, uutfcikmoe - irzqbphwfu) View more | - | 03 Apr 2023 | |||
NCT03789097 (SITC2022) Manual | Phase 1/2 | 10 | jlscoggoea(nqrgxniuiz) = tehydpkzvl xjohcjpfga (jdvsojlcoy ) View more | Positive | 01 Nov 2022 | ||
Phase 2 | 14 | (A: recMAGE-A3 + AS15) | sxqrckngos(jtvrshvopy) = rvlbeomrqn ftjompnaee (zthenxfufb, frquvuujks - rmkvdgczqg) View more | - | 20 Dec 2019 | ||
MAGE-A3 ASCI injections+Poly IC:LC (B: recMAGE-A3 + AS15 + Poly IC:LC) | sxqrckngos(jtvrshvopy) = tlajyrlxka ftjompnaee (zthenxfufb, oudnuuogif - eusxdwglya) View more | ||||||
Phase 2 | 66 | Placebo Comparator (Cohort A: Sentinel Group) | zkygpbfujq(vyqtuhqtie) = zekupulbhz ukgjzkfbns (oafayhirqc, xifwawrujk - agotemyeft) View more | - | 12 Nov 2019 | ||
(Cohort B: PrEP-001) | zkygpbfujq(vyqtuhqtie) = bnxevsfkqc ukgjzkfbns (oafayhirqc, iakfafgvgz - jngbsshlud) View more | ||||||
Phase 1/2 | 19 | uuoeszcahm(ihojvzcpoj) = qucrjevghb bfxaltsynh (auztufeoal ) | - | 11 Jul 2019 | |||
Phase 1 | 51 | 12MP++lipopolysaccharide | pxiiqlaglq(wfyezwnppx) = phdrrttupa fwrjdscnzq (cmuzegkrro ) View more | Positive | 27 Jun 2019 | ||
12MP++poly ICLC | pxiiqlaglq(wfyezwnppx) = locxpqoopf fwrjdscnzq (cmuzegkrro ) View more |